Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
4 Mar 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 Feb 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
9 Jan 24
8-K
Regulation FD Disclosure
12 Dec 23
8-K
Entry into a Material Definitive Agreement
12 Dec 23
8-K
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
20 Nov 23
10-Q
2023 Q1
Quarterly report
1 Nov 23
8-K
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
1 Nov 23
8-K
C4 Therapeutics Announces Chief Financial Officer Succession
5 Sep 23
10-Q
2023 Q1
Quarterly report
8 Aug 23
8-K
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
8 Aug 23
8-K
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
20 Jun 23
8-K
Entry into a Material Definitive Agreement
30 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
4 May 23
EFFECT
Notice of effectiveness
4 May 23
ARS
2023 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
8-K/A
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
23 Feb 23
S-8
Registration of securities for employees
23 Feb 23
POS AM
Prospectus update (post-effective amendment)
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
23 Feb 23
8-K
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
23 Feb 23
8-K
Departure of Directors or Certain Officers
2 Feb 23
8-K
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
9 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
3 Nov 22
8-K/A
Submission of Matters to a Vote of Security Holders
22 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
4 Aug 22
8-K
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
2 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 22
DEFA14A
Additional proxy soliciting materials
17 Jun 22
Latest ownership filings
4
Mark Mossler
10 Apr 24
SC 13G
STATE STREET CORP
10 Apr 24
4
Kenneth Carl Anderson
2 Apr 24
4
Glenn Dubin
2 Apr 24
4
DONNA ROY GROGAN
2 Apr 24
4
Scott N Boyle
8 Mar 24
4
Stewart Fisher
8 Mar 24
4
Kelly Schick
8 Mar 24
4
Kendra Adams
8 Mar 24
4
Jolie Siegel
8 Mar 24
SC 13G/A
WASATCH ADVISORS LP
8 Mar 24
4
Andrew Hirsch
15 Feb 24
4
Andrew Hirsch
15 Feb 24
4
LEONARD REYNO
15 Feb 24
4
Jolie Siegel
15 Feb 24
4
Kelly Schick
15 Feb 24
4
Stewart Fisher
15 Feb 24
4
Scott N Boyle
15 Feb 24
4
Kendra Adams
15 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
WASATCH ADVISORS LP
9 Feb 24
SC 13G
Soleus Capital Master Fund, L.P.
5 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
SC 13G
Betta Investment (Hong Kong) Ltd.
12 Jan 24
SC 13G
Point72 Asset Management, L.P.
4 Jan 24
4
Glenn Dubin
3 Jan 24
4
Kenneth Carl Anderson
3 Jan 24
4
DONNA ROY GROGAN
3 Jan 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
26 Dec 23
SC 13G
COMMODORE CAPITAL LP
22 Dec 23
4
Owen Hughes
20 Nov 23
3
Owen Hughes
20 Nov 23
SC 13G
Lynx1 Capital Management LP
13 Nov 23
4
Kenneth Carl Anderson
3 Oct 23
4
Glenn Dubin
3 Oct 23
4
DONNA ROY GROGAN
3 Oct 23
4
Andrew Hirsch
19 Sep 23
4
Kelly Schick
19 Sep 23